Abstract: An energy management system can include one or more memory devices. The one or more memory devices can store instructions thereon, that, when executed by one or more processors, cause the one or more processors to receive a first dataset from a first energy storage system in a first format and a second dataset from a second energy storage system in a second format. The instructions can aggregate the first dataset and the second dataset into a third dataset, the third dataset having a standard format for a core processing system to execute on. The instructions can execute the core processing system to generate a control decision to control the first energy storage system or the second energy storage system based on the third dataset.

Abstract: An energy management system can include one or more memory devices. The one or more memory devices can store instructions thereon, that, when executed by one or more processors, cause the one or more processors to receive a file including data points of an energy management device coupled to the one or more processors through an interface. The instructions can cause the one or more processors to generate a driver based on the data points of the file. The instructions can cause the one or more processors to execute the driver to read at least one of the data points or write to at least one of the data points via the interface.

Abstract: The present invention relates to diagnosing the risk of developing a need for dialysis and/or predicting a need for dialysis, particularly in patients suffering from renal disorders, comprising the steps of measuring the level of a BNP-type peptide or a variant thereof in a sample from the patient, diagnosing the risk by comparing the measured level of the BNP-type peptide or a variant thereof to at least one reference level. The BNP-type peptide may, for example, be brain natriuretic peptide (BNP), proBNP, NT-proBNP, a variant of BNP, a variant of proBNP, or a variant of NT-proBNP.

Abstract: The present invention relates to the diagnosis of the risk of experiencing a cardiovascular complication in the context of treatment with erythropoiesis stimulating agents (ESA's) such as erythropoietin and derivatives thereof particularly in the context of anemia. More particularly, the invention provides a method for diagnosing the risk of a patient of experiencing a cardiovascular complication as a consequence of future medication with an erythropoiesis stimulating agent (ESA), comprising the steps of (a) measuring the level of a BNP-type peptide in a sample of the patient, (b) diagnosing said risk by comparing the measured level of the BNP-type peptide to at least one reference level. The BNP-type peptide may for example be brain natriuretic peptide (BNP) or the N-terminal fragment of BNP, NT-proBNP. The cardiovascular complication may include complications, such as stroke, transient cerebral ischemic attack, acute-coronary syndrome, myocardial infarction, congestive heart failure etc.

Abstract: Pharmaceutical compositions for the modulation of the immune reaction of warm blooded animals that are derivatives of the 2-oxindole-3-acetic acid or the 2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid are described, and whereby the derivatives can optionally be in an equilibrium with each other.The derivatives included in the pharmaceutical compositions comprise those compounds which are already described in the literature and also new compounds.Furthermore, new derivatives of the the 2-oxindole-3-acetic acid and the 2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid are described, particularly also the the pure antipodes of the mixture of enantiomeres of the 2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid.